مقايسة مستويات الأضداد الذاتية للبروتين الكابح للورم p53 لدى مرضى سرطان رئة في سورية

الملخص EN

Background: p53 mutations are the most common genetic mutations in human cancer, and mutated p53 protein was found to induce p53 Auto-antibodies in sera of patients with various types of cancers, serum p53-Abs measurement may be useful for detection mutant p53 gene.

AIM: Measure p53-Abs in sera from lung cancer patients, and evaluate its correlation to following clinical parameters: gender, smoking, histopathology classification of tumor and staging classification of tumor.

Methods: serum samples from 92 patients with lung cancer and 34 healthy individuals were collected between 2008-2010, patients admitted to the 3 main hospitals in Damascus (ALMouasat, ALAsad and ALMujtahd).

p53-Abs levels were measured by sandwich ELISA (Biodiagnostic, Germany).

Results: p53-Abs were detected in 16/92 (17.4%) lung cancer patients, whereas none of the healthy group sera were positive for p53-Abs, the difference was statistically significant (P=0.009).

There was no significant correlation between the presence of p53-Abs and each of: gender (P=0.96), smoking (p=0.65), histopathology classification of tumor (Small Cell Lung Cancer SCLC or Non Small Cell Lung Cancer NSCLC) (p=0.22), staging classification of SCLC (Limited Disease LD or Extensive Disease ED) (p=0.21).

The presence of p53-Abs was significantly higher in Adenocarcinoma NSCLC patients, in comparison to Squamous Carcinoma NSCLC patients (p=0.04), the presence of p53-Abs was significantly higher in Advanced NSCLC (Stage III, IV), in comparison to Early NSCLC (Stage I, II) (P=0.45).

Conclusion: p53-Abs can be used as Serological tumor marker for lung cancer screening and for early diagnosis